- FREE Shipping with spend over $150
- We've moved! performancepeptidescanada.co same team, same products, same quality.
Have a question about a compound, reconstitution protocol, or COA? Our analytical team responds within one business day.
Independent peptide researchers in Canada need to understand what Research Ethics Boards (REBs) actually govern, and what they don’t. This guide covers the REB framework, how in-vitro work is treated under Canadian research ethics law, how Health Canada oversight differs from REB oversight, and what documentation practices matter for researchers working outside institutional structures.
A Research Ethics Board is an independent committee that reviews research involving human participants before it begins. REBs assess participant risk, confirm that informed consent procedures are adequate, and verify that a study’s potential benefits justify any harms.
Compliance with TCPS 2 is required for institutions receiving federal research funding. Most Canadian universities, hospitals, and government research facilities operate their own REBs under this framework.
REB review under TCPS 2 is triggered by research involving living human participants. The key activities that require approval include:
In-vitro laboratory work, including cell culture experiments, biochemical assays, and receptor binding studies, does not involve human participants and does not trigger REB review under this framework. Neither does research conducted entirely on animal subjects, though animal research at institutional facilities is governed separately by the Canadian Council on Animal Care (CCAC).
| COMPLIANCE NOTICE All compounds referenced on this page are sold by Performance Peptides Canada strictly for in-vitro laboratory and independent research use only. Not approved for human use by Health Canada. No content here constitutes medical advice or a dosing recommendation. |
Preclinical and in-vitro peptide research falls outside the direct scope of TCPS 2. When compounds such as BPC-157 or TB-500 are studied in cell-based models or in animal systems, TCPS 2 REB oversight does not apply in the same way it would for a clinical trial.
The published literature on these compounds has been built almost entirely through preclinical models and in-vitro investigation. None of this work required human-participant REB approval. Understanding that distinction is fundamental to structuring compliant independent research.
TCPS 2 establishes three core principles governing research ethics in Canada: Respect for Persons, Concern for Welfare, and Justice. It operates on a proportional review model, calibrating the level of scrutiny to the level of risk a study presents. Minimal-risk research is eligible for delegated review, a streamlined process that bypasses full board consideration.
The 2022 revision introduced updated provisions relevant to biological materials researchers, including expanded guidance on broad consent for stored biological materials, streamlined multi-jurisdictional review for minimal-risk studies, and new exemptions for specific types of established human cell lines.
Whether REB oversight applies to your work, and how, depends largely on whether you operate inside or outside an institutional structure. The table below breaks down the key differences.
| Factor | Institutional REB | Independent / Commercial REB |
| Who it covers | Researchers affiliated with universities, hospitals, or federally funded institutions | Independent researchers, private labs, and individuals without institutional affiliation |
| TCPS 2 obligation | Mandatory for human-participant research as a condition of federal funding | Not directly required by TCPS 2, but advisable for publishing and collaboration purposes |
| Review process | Full board or delegated review, depending on risk level, governed by institutional REB policies | Varies by provider; most apply TCPS 2 principles and issue documented approval certificates |
| Applies to in-vitro only work? | Generally, no; in-vitro work without human participants sits outside the TCPS 2 scope; check institutional policies | Generally no formal requirement, but maintaining documentation is still best practice |
| When it matters most | Any federally funded research involving humans; institutional animal research under CCAC | Submitting to peer-reviewed journals, entering commercial partnerships, or seeking regulatory approval pathways |
Even when formal REB approval isn’t required, documentation practices matter. If you source research-grade peptide compounds for in-vitro work, build these into your standard protocol:
A written statement documenting that compounds are acquired and used exclusively for in-vitro laboratory research. Specify the research question and experimental model, and confirm no human administration is involved.
Every lot used in your research should be supported by a batch-specific COA from an independent third-party laboratory confirming purity and compound identity. Learn how to read a peptide COA to understand what the data tells you about compound quality.
Maintain records of storage conditions, reconstitution procedures, and lot usage. This supports reproducibility and provides an audit trail if your activities are questioned.
| Performance Peptides Canada supplies batch-verified, HPLC + MS-tested research peptides with downloadable COAs for every lot. 100% domestic Canadian fulfillment. All compounds supplied strictly for in-vitro research use only. Shop the full catalogue at performancepeptidescanada.ca/shop/ |
Not for purely in-vitro work. REB approval under TCPS 2 is triggered by research involving living human participants. Cell culture, biochemical assays, and tissue-based experiments do not fall under TCPS 2 requirements. Institutional animal research may require separate CCAC approval.
TCPS 2 is the Tri-Council Policy Statement governing research ethics across federally funded Canadian institutions. Its three core principles, Respect for Persons, Concern for Welfare, and Justice, guide how REBs evaluate study protocols. Even independent researchers not directly subject to its benefits benefit from understanding the framework.
Health Canada’s authority covers substances manufactured, sold, or imported for human use. Its recent advisories target peptide compounds marketed for human administration, not in-vitro research activity itself. Researchers should source compounds with clear research-use-only documentation and maintain appropriate compliance positioning.
For in-vitro work without human participants, formal REB approval is generally not required. Best practice includes a written research use declaration, batch-specific COAs for all compounds, and storage and handling records. Independent commercial REBs are available for researchers who need documented approval for publication or collaboration.
REBs oversee research involving human participants under TCPS 2. CCAC administers standards for animal-based research. These are separate frameworks with different governing bodies. In-vitro cell-based work with no human or animal subjects is generally outside the direct jurisdiction of both.
| RESEARCH USE ONLY DISCLAIMER: All products supplied by Performance Peptides Canada (Biovantage Labs) are intended strictly for in-vitro laboratory research and independent scientific investigation. They are not approved by Health Canada for human consumption, therapeutic use, or clinical application. This content is provided for informational and educational purposes only. Nothing on this page constitutes medical advice, a clinical recommendation, or a suggestion to administer any compound to humans or animals outside a controlled laboratory setting. Researchers are responsible for ensuring their activities comply with all applicable institutional, provincial, and federal regulations. |
Experience unparalleled research integrity with 99%+ purity guaranteed via third-party HPLC testing, supported by 100% domestic Canadian fulfillment and expert technical guidance for every reconstitution and storage inquiry.
